Interferon beta-1a - Faron Pharmaceuticals

Drug Profile

Interferon beta-1a - Faron Pharmaceuticals

Alternative Names: FP-1201; FP-1201-lyo; MR11A8; Recombinant human interferon beta-1a - Faron Pharmaceuticals; Traumakine

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Faron Pharmaceuticals
  • Developer Faron Pharmaceuticals; Maruishi Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome; Acute lung injury
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Adult respiratory distress syndrome
  • Phase II Abdominal aortic aneurysm; Acute lung injury
  • Discontinued Brain injuries; Spinal cord injuries

Most Recent Events

  • 16 Dec 2016 Phase-II clinical trials in Abdominal aortic aneurysm in Finland (IV) (EudraCT2014-000899-25)
  • 14 Jun 2016 Faron Pharmaceuticals plans to file a CTA with the Finnish Medicines Agency (FIMEA) for Abdominal aorta aneurysm
  • 14 Jun 2016 Faron Pharmaceuticals plans a clinical trial in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top